• NGTF reported $2.97M in revenue, highlighting growth in RaaS and hospitality operations
• Nightfood Holdings leverages AI-driven robots to optimize service workflows and cut down on labor costs
• These updates reflect the company’s broader mission: redefining operational efficiency through autonomous solutions

Nightfood Holdings (d.b.a. TechForce Robotics) (OTCQB: NGTF) is entering a defining chapter in its corporate evolution. The company continues to make expanded inroads into the hospitality and service automation sector, combining AI, robotics, and flexible business models to meet the increased demand for efficiency.  According to its recently filed Form 10-Q for the period ended Dec 31, 2025, NGTF reported revenue of $2.97 million and $129.6 million worth of assets, primarily driven by its Robotics-as-a-Service (“RaaS”) platform and hospitality operations (ibn.fm/zlqzF). The impressive reports highlight the company’s commitment to integrating intelligent automation into real-world service environments and position the company as a leader in next-generation hospitality solutions.

The RaaS platform enables autonomous robots to operate effectively in resorts, hotels, sports arena, restaurants, bars, high traffic live entertainment events and commercial properties. BIM-E (Beverages in Motion – Everywhere) is the company’s automated beverage-serving robot designed to deliver fast, consistent pours of beer, wine, coffee, kombucha, seltzer, and other beverages in high-traffic hospitality environments, helping venues increase throughput and reduce wait times during peak demand. TIM-E focuses on back-of-house logistics operations such as trash removal, dirty linen transport, inventory movement, and internal deliveries. Together, these robotic systems enhance operational efficiency across both guest-facing and service workflows. By automating repetitive tasks, the company reduces labor costs while optimizing operations, enabling human staff to focus on higher-value responsibilities such as personalized guest interactions, customer satisfaction, and operational oversight. (ibn.fm/9mTrK).

The hospitality industry is facing greater pressure from labor shortages and rising operational costs, and TechForce’s AI-driven robots aim to address these issues. The robots use predictive analytics and adaptive learning to respond dynamically to operational changes, provide actionable insights for managers, and optimize workflows. This positions NGTF’s solutions as intelligent partners capable of changing the service delivery industry as we know it (ibn.fm/8Gw6u).

Nightfood’s subscription-based RaaS model enables clients to deploy robots without upfront costs, paying for services on a regular basis while scaling usage as needed. The integration with existing property management systems is designed to be seamless, ensuring minimal disruption during deployment and accelerating adoption across different locations. Its live deployment and pilot programs have reinforced the company’s credibility among investors and clients.

In addition to the immediate operational benefits, the company’s approach provides data-backed insights into workflow optimization, staffing efficiency, and guest interaction patterns. These insights enable properties to continuously refine service operations, improve overall performance, and identify bottlenecks. The company’s emphasis on robotics and AI as core operational tools underscores its broader vision to transform how service industries function in the modern economy.

Looking ahead, the company is exploring expansion into additional service sectors like sports arenas, restaurants, Bars, high-traffic live entertainment events and commercial properties, where labor automation and efficiency can provide a measurable impact. The company’s recent operational strategy highlights its capability to grow Robotics-as-a-Service and its potential to become an integral player in intelligent service automation.

These latest updates highlight the company’s broader mission: redefining operational efficiency through autonomous solutions. Through its blend of robotics, AI, and flexible deployment strategies, the company is creating a scalable, practical framework to run in the background and provide real operational support, while ensuring a competitive advantage in the evolving RaaS market. For industry observers and investors, NGTF’s innovations demonstrate a forward-looking approach that balances operational reliability, cost efficiency, and strategic expansion potential, making projections for the future very promising.

For more information, visit the company’s website at TechForce Robotics.

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF

Disseminated on behalf of MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF) and may include paid advertising.

• MAX Power outlined the next phase of its development plan, following its confirmation of Canada’s first-ever natural hydrogen subsurface system at its Lawson site near Central Butte.
• A cornerstone of the next phase is the commencement of a 3D seismic survey across a 47-square-kilometer area at Lawson, with all required permits and approvals in place.
• MAX Power has also identified more than 80 additional subsurface structures along the Genesis Trend that display geological features analogous to those at Lawson.

MAX Power Mining (CSE: MAXX) (OTC: MAXXF) has taken a notable leap forward in its journey to bring natural hydrogen to the energy forefront; the company announced that it is accelerating its strategy on both its historic Lawson discovery and a broader basin-scale exploration campaign along the 475-kilometer-long Genesis Trend in Saskatchewan. This key step signals that the company is moving from initial proof-of-concept toward commercial evaluation, a transition that could mark a turning point in the burgeoning natural hydrogen sector.

“We are moving rapidly at Lawson with an aggressive ‘months to molecules’ strategy targeting commercial validation,” said MAX Power CEO Ran Narayanasamy. “The repeatability and scalability potential of Genesis creates the opportunity for the birth of the world’s first Natural Hydrogen industry in Saskatchewan, driven not only by geology but technology, a model for the world as this emerging clean energy sector gains momentum. That is the vision and this is why we view Genesis as a potential nation-building project at a pivotal moment in Canada’s history.”

In the announcement, MAX Power outlined the next phase of its development plan, following its confirmation of Canada’s first-ever natural hydrogen subsurface system at its Lawson site near Central Butte. That historic discovery, announced in January, was a key milestone for both the company and the natural hydrogen sector, confirming that naturally occurring hydrogen can be encountered and potentially produced from deep geological formations. The latest news emphasizes that MAX Power is now accelerating toward commercial evaluation by integrating advanced data acquisition, analytical programs and drilling prioritization across its extensive land holdings.

A cornerstone of the next phase is the commencement of a 3D seismic survey across a 47-square-kilometer area at Lawson, with all required permits and approvals in place. This seismic data acquisition, managed by industry expert Tetra Tech, will generate high-resolution subsurface images that are crucial for accurately identifying structural traps where natural hydrogen might accumulate. 

By combining these data with ongoing porosity and permeability analyses at AGAT Laboratories in Calgary and isotopic studies at the University of Windsor, the company intends to develop an integrated dataset to inform its resource modelling and preliminary resource estimation. This analytical workflow is intended to support the siting of a confirmatory well to evaluate commercial potential, a key milestone on the road to proving deliverability.

Beyond the immediate Lawson area, MAX Power has identified more than 80 additional subsurface structures along the Genesis Trend that display geological features analogous to those at Lawson. The company is prioritizing several of these as part of its 2026 multi-well drilling program, leveraging proprietary 2D seismic data integrated into its AI-assisted MAXX LEMI predictive platform to refine drill targeting. By expanding its scope in this manner, the company is working to demonstrate that natural hydrogen systems at Genesis are not limited to a single discovery point but may be repeatable at basin scale, a development that could greatly enhance the scale and commercial attractiveness of natural hydrogen resources in the region.

Natural hydrogen differs from the hydrogen most widely discussed in today’s energy landscape, which is typically produced through manufacturing processes such as steam methane reforming or electrolysis. Natural hydrogen occurs inherently within subsurface geological systems and, if commercially recoverable, offers the prospect of a lower-carbon, potentially lower-cost source of this critical energy carrier. Demonstrating that naturally occurring subsurface hydrogen can be found and produced at scale is at the core of MAX Power’s strategy, and success in this endeavor could position the company as a leader in an emerging clean energy category that may complement existing hydrogen supply chains.

Solid financial backing plays a crucial role in a company’s ability to transition from exploration to potential commercialization. MAX Power’s progress to date, including drilling a historic natural hydrogen well and launching basin-wide exploration efforts, requires sustained investment in data acquisition, drilling, analytical programs and technical infrastructure. 

The company’s ability to deploy capital strategically, while attracting supportive investors, enhances its capacity to navigate the inherent risks of frontier exploration while delivering results that could redefine energy supply dynamics. With a land position of approximately 1.3 million acres of permitted acreage in Saskatchewan, 5.7 million additional acres under application, the scale of MAX Power’s holdings provides a robust platform for long-term exploration and development. 

MAX Power’s leadership has emphasized that the Genesis Trend traverses key industrial regions, including the Regina-Moose Jaw Industrial Corridor, which is home to heavy industry, agricultural processing, logistics and technology infrastructure. Should natural hydrogen be proven commercial at scale, there is potential for domestic supply solutions that align with national energy transition goals while attracting interest from end users keen on securing low-carbon energy inputs. The company is already in discussions with multiple potential end users who have expressed preliminary interest in sourcing natural hydrogen if commercial targets can be demonstrated.

As MAX Power enters this next chapter, the company is focused on playing a defining role in the emerging natural hydrogen landscape. Observers across the energy and investment communities will be watching closely as data from the Lawson 3D seismic survey and subsequent drilling efforts begin to crystallize into geological and commercial insights that could shape the future of clean energy.

For more information, visit www.MaxPowerMining.com.

NOTE TO INVESTORS: The latest news and updates relating to MAXXF are available in the company’s newsroom at https://ibn.fm/MAXXF

Disseminated on behalf of Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) and may include paid advertising.

• Submission of report completes phase 1 of Ucore’s contract with the U.S. Department of Defense to demonstrate the technical capabilities of its RapidSX rare earth separation platform.
• The DoD has identified rare earth processing as a strategic priority under its industrial base strengthening initiatives.
• RapidSX combines aspects of conventional solvent extraction with modern column-based design to enable faster throughput, reduced footprint and potentially lower capital and operating costs.

Submitting a final technical report to a federal partner is more than a procedural step; it signals measurable progress in translating advanced technology into national supply chain capability. Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) recently announced that it has submitted its final phase 1 report to the U.S. Department of Defense [DoD] under its RapidSX(TM) rare earth processing project, marking a significant milestone in the company’s effort to commercialize its separation technology and support domestic rare earth independence.

“Breaking the Chinese advantages of state-backed processing capacity requires a 21st-century approach with digital manufacturing savvy and a reasonable deployment of capital,” said Ucore chair and CEO Pat Ryan, P.Eng. “The completion of the phase I report for the [Department of War] under our OTA and a path to commercialization with phase 2 financial support clearly shows processing independence has become a national security priority for the U.S. administration worthy of sustained investment.”

According to the company, the submission completes phase 1 of Ucore’s contract with the U.S. Department of Defense to demonstrate the technical capabilities of its RapidSX rare earth separation platform. The work has been conducted at Ucore’s RapidSX Commercialization and Demonstration Facility in Kingston, Ontario, which is designed to validate the scalability and efficiency of the company’s proprietary solvent extraction process. The completion of phase 1 positions Ucore to advance into subsequent stages of federal-supported development, subject to continued evaluation and funding decisions.

The importance of this milestone may be best understood within the broader context of rare earth supply chain vulnerabilities. The U.S. Geological Survey has reported that the United States remains significantly dependent on imports for rare earth elements, with China historically dominating global rare earth processing capacity. Rare earth elements are critical inputs for defense systems, electric vehicles, wind turbines, advanced electronics and other high-tech applications. The DoD has identified rare earth processing as a strategic priority under its industrial base strengthening initiatives, reflecting national security concerns about concentrated global supply chains.

Ucore’s RapidSX platform is designed to address this processing bottleneck. Traditional solvent extraction methods used to separate rare earth elements are capital intensive and often require large-scale facilities with complex multistage mixer-settler systems. According to Ucore, RapidSX combines aspects of conventional solvent extraction with modern column-based design to enable faster throughput, reduced footprint and potentially lower capital and operating costs. The company states that RapidSX aims to deliver separation performance comparable to traditional solvent extraction while offering a more modular and scalable solution.

In addition, RapidSX is engineered to separate individual rare earth oxides efficiently from mixed rare earth concentrates, a critical step in transforming mined material into usable end products. Rare earth processing involves the precise separation of chemically similar elements, such as neodymium, praseodymium, dysprosium and terbium, which are essential for permanent magnets used in electric motors and defense technologies. By advancing RapidSX under a Department of Defense-supported program, Ucore is seeking to demonstrate that its platform can support the development of a North American rare earth processing supply chain.

The final phase 1 report submission indicates that Ucore has completed the defined technical objectives for this stage of the contract. While specific performance data were not disclosed, the company emphasized that the milestone reflects continued validation of the RapidSX system’s capabilities under government-supported testing protocols. The completion of phase 1 also reinforces the company’s progress toward commercialization and strengthens its credibility as a participant in federally supported critical minerals initiatives.

The company also reported on phase 2 of the agreement, which was executed last year, is currently underway, with 5 of 20 milestones completed to date. “Work under phase 2 of the agreement will culminate in the construction, commissioning and demonstration of one commercial-scale RapidSX machine at the company’s commercial processing facility in Alexandria, Louisiana,” the company stated. “Subsequent RapidSX machines installed in series will form the first stage of 2,500 tonnes per annum of total rare earth oxide processing for rare earth oxide production.”

Ucore’s broader strategy includes the development of its Louisiana Strategic Metals Complex, which the company envisions as a commercial rare earth processing facility in the United States. This facility is intended to utilize the RapidSX platform to process rare earth feedstock into separated oxides for domestic and allied customers. By pairing its technology development in Canada with planned processing operations in the United States, Ucore is positioning itself as a vertically integrated participant in the rare earth supply chain.

The submission of the final phase 1 report to the Department of Defense is therefore more than an administrative step. It represents tangible progress within a federally recognized effort to strengthen domestic processing capacity. In a sector where technological validation and government alignment are critical to attracting investment and advancing commercialization, meeting contractual milestones can play a decisive role in shaping future funding opportunities and partnership development.

As global competition for critical minerals intensifies and governments prioritize supply chain security, technologies capable of improving efficiency and scalability in rare earth processing will likely attract continued attention. Ucore’s RapidSX platform, now advancing beyond its initial DoD-supported phase, stands at the intersection of technological innovation and national strategic policy. The completion of phase 1 positions the company to continue demonstrating its role in building a more resilient North American rare earth supply chain, one milestone at a time.

For more information, visit www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

Disseminated on behalf of Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) and may include paid advertising.

• The Department of the Interior’s decision to open 2.1 million acres in Alaska’s Dalton Corridor clears a path for expanded mining access tied to the Ambler Road.
• Trilogy Metals holds a 50% interest in Ambler Metals, which owns 100% of the Upper Kobuk Mineral Projects spanning 190,929 hectares in the Ambler Mining District.
• The Arctic deposit hosts 46.7 million tonnes of probable mineral reserves grading 2.11% copper, alongside zinc, lead, gold and silver credits, positioning it among the highest-grade copper projects globally.

The United States’ push to secure domestic supplies of critical minerals has moved from policy discussion to actionable infrastructure decisions. Copper, zinc, silver and cobalt are essential inputs for power grid expansion, data centers, advanced manufacturing and defense systems. As federal agencies reopen access to strategic corridors in Alaska, the Ambler Mining District is re-emerging as one of the most consequential undeveloped mineral belts in North America.

In February 2026, the US Department of the Interior announced the revocation of two long-standing public land withdrawals in Alaska’s Dalton Utility Corridor, opening approximately 2.1 million acres to mining entry. The action was tied to Executive Orders aimed at strengthening domestic energy and mineral production. 

The Dalton Corridor includes portions of the route of the proposed 211-mile Ambler Access Road – the essential transportation link between the Upper Kobuk Mineral Projects and the Dalton Highway. 

By opening 2.1 million acres of previously withdrawn land in the corridor, the federal government has removed a major land-status barrier, strengthening the foundation for road permitting, construction, and long-term infrastructure planning.

The Ambler District: A Domestic Source of Six Critical Minerals

Trilogy Metals (NYSE American: TMQ) (TSX: TMQ) holds a 50% interest in Ambler Metals LLC – a joint venture with South32 Limited – that owns 100% of the Upper Kobuk Mineral Projects in northwestern Alaska. The land package spans approximately 190,929 hectares, or 471,796 acres, across a largely underexplored volcanogenic massive sulphide belt.

The district hosts copper, zinc, lead, silver, cobalt and germanium, metals identified by the US Geological Survey as critical to national supply chains. Copper remains central, given its role in electrification and transmission infrastructure, while zinc supports galvanizing and renewable energy components, and cobalt contributes to battery chemistry.

Two primary deposits anchor the development strategy: Arctic and Bornite.

Arctic: A High-Grade Copper Development Asset

The Arctic deposit is supported by a completed feasibility study and contains 46.7 million tonnes of probable mineral reserves grading 2.11% copper, 2.9% zinc, 0.56% lead, 0.42 g/t gold and 31.8 g/t silver. On a copper-equivalent basis, reserves average approximately 3.7%.

At a base case copper price of $3.65 per pound, the feasibility study outlines a pre-tax net present value of $1.5 billion and a pre-tax internal rate of return of 25.8%. The project is designed as a 10,000 tonne-per-day open pit operation with an estimated 13-year mine life.

Importantly, Arctic is structured to produce three separate concentrates: copper, zinc and a precious metals concentrate. By-product credits materially lower projected cash costs, enhancing economic resilience across commodity cycles.

Bornite: Extending District Life

South of Arctic, the Bornite deposit provides longer-term optionality. A January 2025 preliminary economic assessment outlines a 17-year mine life with average annual production of 109 million pounds of copper. At a $4.20 per pound copper base case, the study indicates a pre-tax NPV of $552 million and a pre-tax IRR of 23.6%.

Bornite hosts 6.527 billion pounds of inferred copper resources. Management has indicated that development sequencing could allow Bornite to extend total district mine activity to over 30 years.

Infrastructure as the Catalyst

In late 2025, federal right-of-way permits were reinstated for the Ambler Road, and the Alaska Industrial Development and Export Authority continues to advance planning. The recent Interior Department decision to open 2.1 million acres north of the Yukon River reinforces the policy direction supporting resource access in the Dalton Corridor.

For Trilogy and its joint venture partner, this alignment between federal infrastructure policy and domestic mineral strategy improves certainty around physical access to the Ambler Mining District.

Capital Position and Federal Support

As of November 30, 2025, Trilogy reported approximately $50 million in cash and no debt. In October 2025, Trilogy, South32 and Ambler Metals also signed a binding letter of intent for a US federal investment of $35.6 million to advance the Upper Kobuk Mineral Projects, for a 10% equity interest in Trilogy. This underscores the growing federal interest in securing domestic sources of copper and other critical minerals.

With an approved $35 million 2026 budget at Ambler Metals focused on permitting, exploration and development milestones, the near-term priority is initiation of mine permitting for the Arctic project and advancement of technical work.

For more information, visit www.TrilogyMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to Trilogy Metals are available in the company’s newsroom at ibn.fm/TMQ

• Beeline Holdings will host a stakeholder call on March 30 to discuss Q4 2025 financial results and operational updates.
• The company reported quarterly double-digit revenue growth in 2025 and ended the year with over $50 million in Balance Sheet  equity and no corporate debt.
• Beeline is scaling an AI-driven mortgage platform designed to shorten closing times and lower origination costs, and is expanding core mortgage, title, and home equity offerings heading into 2026.
• The company is positioning its products for millennials, gig-economy workers, and real estate investors, and recently introduced a blockchain-enabled home equity product, building SaaS revenue channels.

Beeline Holdings (NASDAQ: BLNE),  a fast-growing digital mortgage platform redefining the path to homeownership, announced that it will host a stakeholder update call on March 30, 2026, to review its fourth-quarter 2025 financial results and outline upcoming initiatives, as the digital mortgage platform looks to build on a year of rapid growth. The call will be led by Chief Executive Officer Nick Liuzza and Chief Financial Officer Chris Moe and is scheduled for 5 p.m. ET. (https://ibn.fm/0KGwI).

Beeline operates a fully digital mortgage and title platform through its subsidiary Beeline Loans Inc., offering conventional mortgages alongside alternative lending and equity products for both primary homebuyers and real estate investors.

Management described 2025 as a transition year. Beeline completed its reverse merger with Eastside Distilling in October 2024, divested the legacy spirits business, and repositioned itself as a focused mortgage fintech centered on digital origination, title services, and alternative equity products.

Operationally, Beeline expanded its warehouse lending capacity to $25 million, which management said supports roughly $75 million in monthly mortgage origination volume. In November, the company also completed a $7.4 million registered direct equity offering, strengthening its balance sheet.

At the core of Beeline’s strategy is an AI-driven production model designed to automate customer acquisition and loan processing. The company uses a proprietary chatbot, known internally as “Bob,” to engage borrowers and generate applications, while its workflow engine, Hive, coordinates underwriting, title, and closing functions.

Management says these tools have reduced average closing times to between 14 and 21 days, roughly half the industry average. Beeline also reports a Net Promoter Score above 80, which it attributes to faster processing and a streamlined borrower experience.

Product development was another focus in 2025. Beeline introduced BeelineEquity, a blockchain-enabled home equity product that allows homeowners to access liquidity without taking on traditional debt. Initial transactions were completed by year-end, with a broader pipeline entering 2026.

The equity product is currently targeted at higher-value ZIP codes, where homeowners tend to hold larger amounts of untapped equity. Management has framed this as a complementary offering to its core mortgage business, particularly as aging homeowners look for alternatives to refinancing.

Beeline’s addressable market spans two large demographic groups. For younger borrowers, especially millennials and gig-economy workers, the company aims to simplify mortgage access through AI-assisted underwriting and near-real-time eligibility assessments. For investors, Beeline offers financing for rental and investment properties, an area where traditional lenders often impose tighter constraints.

According to recent reports, only 54.9% of millennials owned homes in 2024, highlighting the structural challenges facing first-time buyers (https://ibn.fm/ZJFye). Beeline’s platform is designed to reduce friction for these borrowers while also supporting small-scale property investors.

For more information, visit the company’s website at www.MakeABeeline.com.

NOTE TO INVESTORS: The latest news and updates relating to BLNE are available in the company’s newsroom at https://ibn.fm/BLNE

• LIXTE Biotechnology Holdings and the company’s subsidiary, Liora Technologies, both develop products that aim to improve outcomes for cancer patients
• Specifically, Liora’s Linac for Image Guided Hadron Therapy (“LiGHT”) System and LIXTE’s LB-100 work together to fight cancer
• As a result, the companies are building a new cancer care ecosystem that hopes to boost the effectiveness of treatments, while also help them be more accessible for a wider range of patients

Recently, LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company, acquired Liora Technologies, a company that is aiming to transform cancer care with innovative compact proton therapy.

Specifically, Liora has created the LiGHT System, which is believed to provide many advantages over other proton therapy methods and systems that are currently available. While it is smaller in size, the system can be deployed quickly and is much more cost-effective to build and use. 

The system also eliminates mechanical energy degraders, reduces proton loss and enables more efficiency as it adjusts energy electronically. It also allows for much more precise dosing and lets you change energy levels much faster than many other methods.

The LiGHT system synergizes incredibly well with LIXTE’s lead clinical candidate and main product, LB-100, a proprietary small-molecule inhibitor of protein phosphatase 2A (“PP2A”) that boosts the activity and effectiveness of chemotherapy and immunotherapy. It has demonstrated a favorable safety profile in Phase 1 clinical trials and is supported by more than two dozen published preclinical and translational studies. The compound is currently being evaluated in multiple clinical programs targeting solid tumors with limited treatment options.

Together, the companies, and their flagship products and systems, are building a new cancer care ecosystem. Specifically, Liora’s radiotherapy technology complements LIXTE’s LB-100 approach.

The LiGHT System works to effectively destroy cancer cells by precisely delivering the right amount of radiation in the right spots. This synergizes well with LB-100, as the compound not only makes cancer cells more vulnerable to the radiation, but also helps to prevent these cancer cells from being able to repair themselves after being damaged.

Simply put, the LB-100 may weaken the cancer cells, thus boosting how well the radiation from the LiGHT System is able to damage them, while also preventing the cells from being able to recover after being damaged by the radiation.

As a result, the pair has the potential to become a multi-modal cancer care platform that helps patients enjoy more effective cancer treatments. The acquisition allows LIXTE to test the drug-device combo in trials and see just how much more effective and efficient the ecosystem may be than other currently available methods.

About LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT)

LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical company that’s developing cancer therapies built around a novel biological target. Instead of introducing standalone treatments, the company is focused on enhancing the effectiveness of established cancer therapies and addressing challenges that limit outcomes in oncology.

For more information, visit the company website at https://lixte.com.

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

• Appointment of fusion researcher Fabrice David adds scientific oversight as commercialization plans advance.
• Travis Yakimishyn joins as Chief Electrical & Power Systems Officer to lead utility-scale integration.
• The company is transitioning to American Fusion Inc. following its merger with Kepler Fusion Technologies, with filing and audits nearing completion as the company prepares for SEC reporting status.
• Management reiterates goal of deploying a 100-megawatt operational unit by year-end 2026, with Kepler‘s plan to sell electricity on a per-kilowatt basis to utilities and industrial customers.

Renewal Fuels (OTC: RNWF) (d/b/a American Fusion), an advanced energy platform company focused on the development and commercialization of fusion energy technologies, is working to advance its Texatron(TM) aneutronic fusion system, while simultaneously strengthening governance, engineering leadership and regulatory positioning.

In February, the company appointed Fabrice David as an independent director (https://ibn.fm/yJaLP). David is described as a scientific researcher and inventor with more than 130 publications and multiple patents spanning advanced energy systems and experimental physics. As an Independent Director, David will provide scientific and technical oversight, insight into intellectual property strategy, and independent judgment supporting disciplined governance as the company advances its Texatron platform.

Chief Executive Brent Nelson said in a statement that David’s background in fusion-adjacent research, intellectual property development and scientific governance aligns with the company’s transition toward commercialization. “His experience across experimental validation, intellectual property development, and international scientific collaboration strengthens our Board as we continue building a scalable fusion energy platform,” Nelson said.

Richard Hawkins, Chairman and CEO of Renewal Fuels, Inc., added that David’s background reflects decades of disciplined research and intellectual rigor across fusion-adjacent systems and advanced energy technologies. “His perspective supports our commitment to long-term value creation, strong governance, and responsible innovation.”

Independent oversight is particularly relevant in fusion, where technical claims often precede commercial validation. American Fusion is still in the development phase. The company reports stable plasma formation at sub-fusion temperatures using a proprietary pulsed torsatron configuration and deuterium–helium-3 fuel, but it has not demonstrated net-energy gain.

Alongside the board appointment, the company named Travis Yakimishyn as Chief Electrical & Power Systems Officer (https://ibn.fm/PZRYy). Yakimishyn is a licensed professional engineer with experience in high-voltage systems, substations and grid interconnection planning.

In his role, Yakimishyn will oversee the electrical architecture and grid integration strategy for Kepler’s Texatron platform. His responsibilities include advancing scalable electrical design standards, coordinating interconnection pathways, aligning protection and control systems with commercial deployment requirements, and ensuring that the company’s power systems infrastructure is engineered for long-term operational stability.

Nelson said Yakimishyn’s role in bridging plasma physics and utility-scale electrical engineering has been instrumental. “His deep expertise in high-voltage systems and infrastructure deployment significantly strengthens our ability to transition Texatron(TM) from advanced development into commercial operation.”

In a follow-up interview, Nelson and Kepler Chief Technology Officer Dr. John E. Brandenburg outlined a 2026 roadmap centered on delivering a 100-megawatt fusion power unit (https://ibn.fm/4bddO).

Nelson said component integration and subsystem validation are progressing toward full-scale assembly. He emphasized that Kepler’s platform is compatible with existing grid infrastructure, noting that capacitor banks, transformers, and inverters used in solar and wind installations are directly adaptable to Kepler’s system.

“Our engineering milestones continue to align with our deployment schedule,” Nelson said. “We’re now moving from proof-of-concept validation into full-scale assembly and integration. Every step reinforces our confidence that our first 100-megawatt unit will be grid-ready in partnership with our North Texas utility collaborators.”

The company’s commercial model centers on power-as-a-service. Rather than licensing reactor designs, Kepler intends to sell electricity on a per-kilowatt basis at pricing it says is competitive with hydropower and other baseload sources.

Nelson described a developing pipeline that includes utilities, industrial operators and remote communities seeking continuous, emission-free generation. “We’re seeing strong demand across multiple sectors,” Nelson noted. “Industrial customers want predictable, low-cost power. Remote communities want reliability without high maintenance. And utilities want scalable, dispatchable clean energy. Our model delivers all three while maintaining compelling margins.”

Discussions have also involved government entities, including the Department of Defense and NASA, for multiple applications ranging from military microgrids to lunar surface power concepts to resilient infrastructure for remote or disaster-prone regions.

The company’s broader corporate structure is also evolving. Renewal Fuels has filed a corporate action with FINRA to formally change its legal name to American Fusion Inc. The company said its Form 10 registration statement under the Securities Exchange Act of 1934 is substantially complete, with EDGAR access pending. A PCAOB audit covering fiscal 2024 and 2025 is nearing completion. Achieving SEC reporting status would move the company into a more transparent regulatory framework, potentially widening its investor base.

The company’s recent appointments suggest an effort to add technical depth and governance discipline before approaching large-scale infrastructure investors. Nelson reiterated the company’s belief that the Texatron platform is a high-value opportunity for investors, offering an attractive blend of competitive pricing, broad applicability, and the absence of radioactive waste or long-term environmental liabilities.

“We’re building a platform that can scale globally,” Nelson said. “Our technology is designed for rapid deployment, minimal maintenance, and seamless integration with existing grid assets. We believe this positions Kepler to become one of the most impactful clean-energy providers of the next decade.”

For more information, visit the company’s website at www.AmericanFusionEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to RNWF are available in the company’s newsroom at https://ibn.fm/RNWF

• “The EMA’s positive opinion signifies an important step for Soligenix as we continue to advance the program,” says company CEO.
• The designation provides incentives that may include protocol assistance, reduced regulatory fees and up to 10 years of market exclusivity following approval.
• Dusquetide is classified as an innate defense regulator, a type of compound designed to modulate the body’s innate immune system rather than suppress it outright.

For patients living with rare inflammatory diseases, regulatory milestones can mark the difference between stalled research and meaningful therapeutic progress. A positive opinion from the European Medicines Agency (EMA) not only validates a drug’s scientific rationale but can also unlock development incentives that accelerate its path forward. In that context, Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing treatments for rare diseases and areas of unmet medical need, announced that it has received a positive opinion from the EMA’s Committee for Orphan Medicinal Products for its pipeline product dusquetide in the treatment of Behcet’s disease.

“We are extremely pleased to have received the positive opinion from the COMP and look forward to the European Commission granting the orphan drug designation for the SGX945 program,” said Soligenix CEO and president Christopher J. Schaber, PhD. Behçet’s disease is an area of unmet medical need, with up to 18,000 people in the U.S., 50,000 people in Europe, 350,000 people in Türkiye and as many as 1 million people worldwide affected by this incurable disease.

“Given the clinically meaningful improvements seen in our phase 2 proof-of-concept study in patients with oral aphthous ulcers due to Behçet’s disease, we are hopeful dusquetide will have a role to play in helping underserved patients suffering from this difficult to treat and chronic auto-immune disease,” Schaber continued. “The EMA’s positive opinion signifies an important step for Soligenix as we continue to advance the program and adds significantly to the existing intellectual property estate surrounding this novel technology.”

In the European Union, orphan medicinal product designation is granted to therapies intended to treat life-threatening or chronically debilitating conditions affecting no more than five in 10,000 people, according to the European Commission. The designation provides incentives that may include protocol assistance, reduced regulatory fees and up to 10 years of market exclusivity following approval, as outlined by the European Medicines Agency. These benefits are designed to encourage companies to invest in treatments for rare diseases that might otherwise lack sufficient commercial incentive.

Behcet’s disease is a rare, chronic, multisystem inflammatory disorder characterized by recurrent oral and genital ulcers, skin lesions and, in some cases, inflammation affecting the eyes, joints, blood vessels and nervous system. The National Library of Medicine describes Behcet’s as a complex autoimmune-related condition that can lead to serious complications, including vision loss when ocular inflammation is severe. While the disease is more common along the historic Silk Road regions such as Türkiye and parts of the Middle East and East Asia, it remains rare in Europe and North America, supporting its qualification for orphan designation under EU criteria.

There is currently no cure for Behcet’s disease. Treatment generally focuses on reducing inflammation and managing symptoms through corticosteroids, immunosuppressive medications and biologic agents. Because the disease can relapse unpredictably and may require long-term immunosuppressive therapy, patients often face ongoing risks associated with chronic immune modulation. This underscores the importance of developing novel approaches that aim to regulate immune responses more precisely rather than broadly suppress them.

Soligenix’s investigational therapy for Behcet’s disease is dusquetide, the active pharmaceutical ingredient in SGX945. According to the company, dusquetide is classified as an innate defense regulator, a type of compound designed to modulate the body’s innate immune system rather than suppress it outright. Dusquetide targets the p62/sequestosome-1 signaling pathway, which plays a role in regulating inflammation and immune responses. By modulating this pathway, dusquetide is intended to reduce inflammatory damage while preserving normal immune defense mechanisms.

Soligenix has previously evaluated dusquetide in other inflammatory settings. The company reports that dusquetide has been studied in clinical trials for oral mucositis and other immune-related conditions, providing clinical experience with the molecule’s safety and mechanism of action. The rationale for its use in Behcet’s disease stems from its potential ability to rebalance dysregulated immune responses that drive ulcer formation and systemic inflammation.

The positive opinion from the Committee for Orphan Medicinal Products does not itself constitute marketing approval, but it is a critical regulatory milestone. Following a positive opinion, the European Commission often issues a formal decision on orphan designation. If granted, the designation may provide Soligenix with development incentives and regulatory support that could facilitate further clinical advancement.

For patients living with Behcet’s disease, the potential availability of a new therapeutic option that aims to regulate immune response rather than broadly suppress it could represent a meaningful advancement. Chronic inflammation and recurrent ulcerations can significantly impair quality of life, and current therapies may not fully control disease activity or may carry long-term safety considerations. The advancement of dusquetide under an orphan designation framework signals continued momentum in rare disease research.

As Soligenix moves forward, the European Medicines Agency’s positive opinion provides both validation and strategic leverage. In rare-disease drug development, regulatory alignment and incentive programs can make a substantial difference in the feasibility of bringing new treatments to market. For Soligenix, this milestone reinforces its commitment to addressing rare inflammatory disorders and strengthens the foundation for continued development of dusquetide in Behcet’s disease.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

• The company’s core innovation, the HeartBeam System, is positioned as the first cable-free, high-fidelity ECG system capable of capturing the heart’s electrical signals from three distinct directions.
• HeartBeam’s strategy is built around addressing a long-standing gap in cardiac care.
• Looking forward, HeartBeam is focused on advancing both its hardware and software platforms.

HeartBeam (NASDAQ: BEAT) stands at a pivotal point in its development as a medical technology company focused on transforming how cardiac arrhythmias are detected, evaluated and monitored. Headquartered in Santa Clara, California, HeartBeam is building a platform designed starting with its FDA-cleared synthesized 12-lead ECG system to bring clinically meaningful ECG data out of traditional healthcare facilities and into more accessible, patient-centered settings.

The company’s core innovation, the HeartBeam System, is positioned as the first cable-free, high-fidelity ECG system capable of capturing the heart’s electrical signals from three distinct directions. Those signals are then synthesized into a 12-lead ECG using a personalized transformation matrix. This unique approach delivers exceptional data fidelity through a portable device that can be used by patients wherever they are when arrhythmia symptoms occur – without being in a healthcare facility, the currently cleared indications for use.

HeartBeam’s strategy is built around addressing a long-standing gap in cardiac monitoring. Conventional 12-lead ECG systems, which are the clinical standard for evaluating arrhythmias and ischemic events, require wired electrodes, trained personnel and clinical infrastructure. At the same time, most consumer and portable ECG devices rely on single-lead or low-resolution signal capture, which limits their utility.

HeartBeam’s technology is designed to bridge this gap by combining portability with clinical-grade signal quality. In the near term, HeartBeam is focusing on bringing its technology to market through a limited launch in early 2026, following FDA clearance for the company’s 12-lead ECG synthesis software for arrhythmia assessment in December 2025.

Looking forward, HeartBeam is focused on advancing both its hardware and software platforms. The company’s proprietary system integrates embedded electrodes into a handheld, credit card-sized device, allowing patients to record cardiac signals without cables or external electrodes. In addition, the company has developed a working prototype of a 12-lead ECG extended wear patch monitor, which has the potential to be a best-in-class offering in an established multi-billion-dollar market with reimbursement.

In parallel with its hardware development, HeartBeam is pursuing a heart attack detection indication approval from FDA in the near future. According to the U.S. Centers for Disease Control and Prevention, heart disease continues to be the leading cause of death in the United States, responsible for roughly one in every five deaths each year. The company has already generated compelling proof-of-concept data and plans to generate additional clinical evidence to support the FDA submission.

The company is also building advanced analytical software designed to interpret the complex electrical data generated by the system. HeartBeam’s AI-based analysis tools are intended to help clinicians compare recordings to patient-specific baselines, identify clinically meaningful changes, and support faster decision-making. This integration of hardware and software reflects a broader digital health trend in which diagnostics, data analytics and remote monitoring are converging into unified platforms rather than standalone devices. The company plans to submit for FDA clearance of its AI-driven algorithms in the future.

The company’s broader vision remains centered on decentralizing cardiac detection. Most cardiac events occur outside clinical settings, and delays in obtaining meaningful ECG data can lead to missed diagnoses, unnecessary emergency visits and delayed treatment. HeartBeam’s technology is intended to reduce these gaps by enabling patients to capture clinically relevant data at the moment symptoms occur, while allowing clinicians to review and interpret that data remotely. This model aligns with the continued expansion of telehealth, remote patient monitoring and home-based care across healthcare systems.

In addition to the limited launch of its FDA cleared technology in early 2026, HeartBeam’s progress also reflects a long-term growth strategy looking to capture significant unmet need. The company continues to invest in regulatory alignment, technical validation and system integration as foundational steps toward broader market adoption. Its groundbreaking 3D ECG approach, cable-free hardware design and future AI-driven analysis positions it within a differentiated niche of the cardiac care market, one focused on portability without sacrificing clinical precision.

For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

• Frontieras’ patent portfolio includes protection across five continents and nine countries, covering approximately 85% of global coal production.
• The FASForm(TM) process is designed as a closed-loop, zero-waste system that converts coal into multiple market-ready energy and industrial products.
• Long-term feedstock and product offtake frameworks are in place for the company’s flagship commercial facility.
• The Mason County project is structured as a large-scale infrastructure development with established engineering, construction, operations, logistics, and insurance partners.
• Frontieras’ commercialization strategy focuses on replicable facilities serving established energy and chemicals markets with existing demand.

Frontieras North America is an energy and environmental technology company focused on redefining how coal and other solid hydrocarbons are utilized within modern energy and industrial systems. Rather than treating coal as a fuel to be burned, the company applies patented processing technology to reform solid hydrocarbons into multiple market-ready energy and industrial products designed for existing global markets.

The company’s approach is rooted in extracting greater value from abundant natural resources through industrial innovation, addressing inefficiencies historically associated with conventional coal use. By separating coal into gases, liquids, and purified solid carbon, Frontieras positions coal as a versatile feedstock capable of supporting transportation, manufacturing, agriculture, and industrial infrastructure demand.

Frontieras emphasizes closed-loop, zero-waste processing as a means of producing energy products more efficiently while reducing emissions and unused byproducts.

Products and Projects

Frontieras’ core platform is FASForm(TM), a patented Solid Carbon Fractionation process that deconstructs coal by extracting volatiles, moisture, and contaminants. The process produces hydrogen, methane, naphtha, diesel, aviation fuel, and FASCarbon(TM), a low-sulfur technical carbon product.

The company is developing its first commercial-scale FASForm(TM) facility in Mason County, West Virginia, an estimated $850 million project designed to process approximately 7,500 tons of coal per day, or about 2.7 million tons annually. The facility is supported by a 10-year feedstock MOU using Pittsburgh #8 coal and a 10-year offtake LOI covering 100% of produced fuels, FASCarbon(TM), sulfuric acid, and fertilizer.

Engineering, construction, operations, logistics, and insurance partners are under executed agreements, and the project has completed FEL 1 and FEL 2, with substantial FEL 3 underway. Following its initial Mason County development, Frontieras plans to deploy additional FASForm(TM) facilities in West Virginia, Texas, and Wyoming, with longer-term international deployment in markets where its patent portfolio is in force.

Market Opportunity

Frontieras targets established global energy and chemicals markets with a combined estimated value exceeding $2.1 trillion. The company’s product portfolio aligns with large, existing demand across diesel, hydrogen, naphtha, jet fuel, technical carbon – coke, industrial chemicals, and fertilizer markets. These products are core industrial inputs with long-established supply chains, entrenched end-use applications, and global pricing benchmarks, reducing reliance on the creation of new or speculative markets.

These markets serve essential roles across transportation, agriculture, industrial machinery, aviation, steel manufacturing, petrochemicals, and food production, supporting continuous demand driven by infrastructure, manufacturing, and population growth. The planned design capacity of the first FASForm(TM) facility is approximately 7,500 tons per day, or about 2.7 million tons annually — equivalent to roughly 0.5% of current U.S. coal production. This design framework is intended to enable Frontieras to scale output incrementally while remaining aligned with existing market capacity, logistics networks, and demand profiles.

Leadership Team

Matthew McKean, Co-Founder & Chief Executive Officer, leads Frontieras’ overall strategy and execution and brings more than 25 years of experience across finance, operations, and business leadership. He previously co-founded a mortgage banking firm that grew into one of the largest originators in the southwestern U.S. before a successful exit, followed by senior leadership roles within large real estate finance organizations. McKean has been an active member of the CEO mentoring organization Vistage, advising companies across construction, finance, infrastructure, and consumer sectors. He holds a Bachelor of Science in Human Nutrition with an emphasis in Chemistry from Arizona State University and completed pre-med coursework.

Joseph Witherspoon, P.E., Co-Founder & Chief Technology Officer, is the inventor of the FASForm(TM) process and the author of the company’s core patents. He brings extensive experience in petroleum refining, natural gas processing, and chemical engineering from senior roles at Chevron, Enterprise Products, Sinclair Oil, and Marathon Petroleum. As a Process Design Engineer and Major Capital Project Manager, Witherspoon has led projects delivering significant operational and economic improvements. He holds a Bachelor of Science in Chemical and Fuels Engineering from the University of Utah and is a licensed Professional Engineer.

Andrea Moran, Chief Commercial Officer, oversees Frontieras’ commercialization strategy, capital formation, and go-to-market execution. She brings more than 25 years of experience in operations, management, and business development across the energy and infrastructure sectors. Prior to Frontieras, Moran served as Co-Founder and Vice President of Business Development at Yield Power Group, a project finance firm supporting energy and infrastructure projects ranging from $100 million to over $1 billion. She holds a Bachelor of Science in Political Science from the University of Wisconsin and serves on philanthropic and advisory boards.

José López, Chief Financial Officer, leads Frontieras’ financial strategy, operations, and capital planning. He brings over 20 years of experience in global finance and accounting, including senior roles at multinational public companies. López began his career at PwC’s external assurance practice, working across Houston, London, and The Hague. His background includes SEC reporting, corporate governance, FP&A, mergers and acquisitions, and capital markets transactions. He holds a Bachelor of Science in Accounting and Finance from the University of Houston–Clear Lake and is a licensed Certified Public Accountant.

For more information, visit the company’s website at www.Frontieras.com.

NOTE TO INVESTORS: The latest news and updates relating to Frontieras are available in the company’s newsroom at https://ibn.fm/Frontieras